We're investing over £280,000 to accelerate the development of new Parkinson's drugs
Date
Research news
Date
Initial results suggest the drug SNT-4728 was able to reduce inflammation in an area of the brain that controls movement and motivation.
Date
Researchers have discovered that changes in a gene cause a range of neurological conditions that involve a loss of brain cells, including Parkinson's.
Date
We're working with EndLyz Therapeutics to fund the development of 2 potential drugs that could clear cells of unwanted materials that contribute to the causes of Parkinson's.
Date
A study, part-funded by Parkinson's UK, has uncovered important insights into why some people with Parkinson's develop dementia, while others don't.
Date
New research shows changes to microbes in the gut can be detected before Parkinson's symptoms appear.
Date
The therapy has been given conditional, limited approval for people in Japan based on the results of a 2-year research study.
Date
A £1.7 million partnership will combine data from over 20,000 people to accelerate the search for new treatments for Parkinson's.
Date
Herantis Pharma Plc to receive almost £7 million from the European Union for a phase 2 trial of HER-096 that has the potential to slow or stop Parkinson's.
Date
New recommendations aim to improve the design of research trials involving brain surgery and support for participants.
Date
3 leading researchers have now been appointed to help kick start our new research centre unlocking new ideas for treating Parkinson's.